Lin A - Search Results

1

A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study.

Pollock Y, Zhang L, Kenfield SA, Van Blarigan EL, Rodvelt T, Rabow M, Macaire G, Weinberg R, Topp K, Friedlander T, Lin A, Fong L, Kim W, Ma B, Hough J, Lee M, Paciorek A, Ryan CJ, Chan JM, Small E, Aggarwal R. Pollock Y, et al. Among authors: lin a. Urol Oncol. 2021 Oct;39(10):730.e9-730.e15. doi: 10.1016/j.urolonc.2021.05.032. Epub 2021 Jul 23. Urol Oncol. 2021. PMID: 34304981 Clinical Trial.

2

Clinical trials in patients with biochemically relapsed prostate cancer.

Lin AM, Rini BI, Small EJ. Lin AM, et al. BJU Int. 2006 May;97(5):905-10. doi: 10.1111/j.1464-410X.2006.06124.x. BJU Int. 2006. PMID: 16643469 Review.

3

Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale.

Ryan CJ, Lin AM, Small EJ. Ryan CJ, et al. Urol Oncol. 2006 May-Jun;24(3):250-3. doi: 10.1016/j.urolonc.2005.11.021. Urol Oncol. 2006. PMID: 16678059 Review.

4

A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy.

Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. Lin AM, et al. BJU Int. 2006 Oct;98(4):763-9. doi: 10.1111/j.1464-410X.2006.06396.x. BJU Int. 2006. PMID: 16796694 Clinical Trial.

5

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells.

Lin AM, Hershberg RM, Small EJ. Lin AM, et al. Urol Oncol. 2006 Sep-Oct;24(5):434-41. doi: 10.1016/j.urolonc.2005.08.010. Urol Oncol. 2006. PMID: 16962496 Review.

6

Intermittent chemotherapy for metastatic hormone refractory prostate cancer.

Lin AM, Ryan CJ, Small EJ. Lin AM, et al. Crit Rev Oncol Hematol. 2007 Mar;61(3):243-54. doi: 10.1016/j.critrevonc.2006.10.002. Epub 2006 Dec 11. Crit Rev Oncol Hematol. 2007. PMID: 17161610 Review.

7

Prostate cancer update: 2006.

Lin AM, Small EJ. Lin AM, et al. Curr Opin Oncol. 2007 May;19(3):229-33. doi: 10.1097/CCO.0b013e3280ad43bd. Curr Opin Oncol. 2007. PMID: 17414641 Review.

8

A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.

Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. Lin AM, et al. Clin Genitourin Cancer. 2007 Jun;5(5):323-8. doi: 10.3816/CGC.2007.n.011. Clin Genitourin Cancer. 2007. PMID: 17645829 Clinical Trial.

9

Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome.

Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. Ryan CJ, et al. Among authors: lin a. J Urol. 2007 Dec;178(6):2372-6; discussion 2377. doi: 10.1016/j.juro.2007.08.011. Epub 2007 Oct 22. J Urol. 2007. PMID: 17936834 Clinical Trial.

10

A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer.

Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. Ryan CJ, et al. Among authors: lin a. BJU Int. 2008 Feb;101(4):436-9. doi: 10.1111/j.1464-410X.2007.07330.x. BJU Int. 2008. PMID: 18234062

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,014 results

Search Page

Filters